Onkologie 2008

Was ist neu?

• Monoklonale Antikörper gegen den EGF-Rezeptor: Fortschritt bei Kopf-Hals- und Kolonkarzinomen

• VEGF-Blockade mit Bevacizumab: Zulassungserweiterung beim Mamma-, nicht-kleinzelligen Lungen- und Nierenzellkarzinom.

• Molekulare Therapiestrategien mit Tyrosinkinase-Inhibitoren: Fortschritte bei der Therapie des Mamma- und Leberzellkarzinoms.

• mTOR Inhibition: Weitere Option zur Behandlung des fortgeschrittenen/metastasierten Nierenzellkarzinoms.

• Ixabepilon beim metastasierten Mammakarzinom: Neue Zytostatika im Zeitalter der „targeted therapy”?

• Kleinzelliges Lungenkarzinom: Prophylaktische Ganzhirnbestrahlung auch im Stadium der „extended disease”?

• Metastasenchirurgie beim metastasierten kolorektalen Karzinom: Indikation zur perioperativen Chemotherapie?

Literatur

• 1 Amado R G. et al . Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer.  JCO. 2008;  26 1626-1634
• 2 Di Leo A. et al . Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients.  Proc Am Soc Clin Oncol JCO. 2007;  25 (suppl) , abstr 1011
• 3 Escudier B. et al . Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.  The Lancet. 2007;  370 2103-2111
• 4 Geyer C E. et al . Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data.  Proc Am Soc Clin Oncol JCO. 2007;  25 (suppl) , abstr 1035
• 5 Hudes G. et al . Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma.  N Engl J Med 2007. ;  356 2271-81
• 6 Llovet J. et al . Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial).  Proc Am Soc Clin Oncol JCO. 2007;  25 (suppl) , abstr LBA1
• 7 Manegold C. et al . Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704.  Proc Am Soc Clin Oncol JCO. 2007;  25 (suppl) abstr LBA751
• 8 Miller K. et al . Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer.  New England Journal of Medicine. 2007;  357 2666-2676
• 9 Nördlinger B. et al . Final results of the EORTC Intergroup randomized phase III study 40 983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases.  Proc Am Soc Clin Oncol JCO. 2007;  25 (suppl) abstr LBA5
• 10 Perez E A. et al . Efficacy and Safety of Ixabepilone (BMS-247 550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine.  JCO. 2007;  (10) 3407-3414
• 11 Sandler A. et al . Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer.  N Engl J Med 2006. 2006;  355 2542
• 12 Slotman B. A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08 993 - 22 993).  Proc Am Soc Clin Oncol JCO. 2007;  25 (suppl) abstr 4
• 13 van Cutsem E. et al . Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial.  Proc Am Soc Clin Oncol JCO. 2007;  25 abstr 4000
• 14 Cutsem. et al . Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer.  JCO. 2007;  25 1658-1664
• 15 Vermorken J. et al . Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - Results of a randomized phase III (Extreme) study.  Proc Am Soc Clin Oncol JCO. 2007;  25 (suppl) abstr 6091